MedPath

Clinical Trial News

Summit Therapeutics' Ivonescimab Shows Promise in Lung Cancer Trial

  • Summit Therapeutics announced positive Phase 3 trial results for ivonescimab in non-small cell lung cancer.
  • The study, conducted in China, demonstrated a statistically significant improvement in the primary endpoint.
  • Ivonescimab reduced the risk of disease progression or death by 49% compared to other treatments for certain patients.
  • Shares of Summit Therapeutics experienced a significant surge following the announcement of these positive results.

Grail's Galleri Test Pursues FDA Approval for Multi-Cancer Early Detection

• Grail's Galleri test, designed for early detection of over 50 cancer types from a single blood sample, is seeking FDA approval to broaden its accessibility. • The company is actively working towards FDA premarket approval for Galleri, utilizing data from NHS-Galleri and PATHFINDER 2 studies, aiming for submission by 1H2026. • Cost-cutting measures, including a 30% workforce reduction, aim to extend the company's cash runway and support the pursuit of Medicare coverage post-FDA approval. • Galleri has already seen commercial success as a Laboratory Developed Test, with over 215,000 tests prescribed by 11,000 healthcare providers, highlighting its potential impact.

Embecta's Tubeless Insulin Patch Pump Receives FDA Clearance for Diabetes Management

  • Embecta Corp. secures FDA 510(k) clearance for its tubeless insulin patch pump designed for adults with type 1 and type 2 diabetes.
  • The system features a 300U insulin reservoir patch pump, lasting up to 3 days, and a Bluetooth-enabled controller with a color touchscreen.
  • Clinical feedback informed the design, ensuring the 300U reservoir meets the 3-day insulin needs of 64% of type 2 diabetes patients.
  • Embecta plans to develop a closed-loop system with an insulin dosing algorithm to further advance diabetes management.

Vaginal Microbiome Signature Linked to Increased HIV Risk Identified

• Researchers have identified a specific signature of vaginal bacteria and inflammatory proteins associated with elevated HIV infection risk in women. • The study pinpointed 14 bacterial taxa and six inflammatory proteins, where the presence of all markers significantly increased HIV risk. • Lactobacillus crispatus was identified as a bacterial species associated with protection against HIV infection, offering potential preventative strategies. • Findings suggest potential for targeted interventions, such as antibiotics or probiotics, to modify the vaginal microbiome and reduce HIV risk.

Genus PLC Eyes FDA Approval for PRRS Resistant Pig Amidst Strategic Advancements

• Genus PLC reported preliminary fiscal year results, highlighting progress in commercializing its Porcine Reproductive and Respiratory Syndrome (PRRS) Resistant Pig and expanding its porcine business in China. • The company anticipates FDA approval for its gene-edited pig in 2025 and has made submissions to authorities in Canada and Japan, with constructive initial dialogues. • Genus is implementing its Value Acceleration Program (VAP) to transform its ABS (bovine) business, expecting significant profit growth in FY 2025. • Despite some profit declines in specific regions, Genus expects significant profit before tax (PBT) growth in the next fiscal year, driven by strategic initiatives and R&D investments.

Avacta's AVA6000 Shows Durable Responses in FAP-Positive Solid Tumors with Reduced Toxicity

  • AVA6000 demonstrates encouraging efficacy with durable RECIST responses in patients with FAP-positive solid tumors, aligning with a favorable safety profile.
  • The pre|CISION™ technology enables tumor-specific doxorubicin release, reducing cardiac toxicity and other side effects compared to conventional doxorubicin.
  • Pharmacokinetic analysis reveals AVA6000 extends doxorubicin's half-life and limits its distribution into normal tissues, enhancing tumor exposure.
  • Clinical data supports the potential of AVA6000 to treat a broad range of solid tumor patient populations with unmet clinical needs.

Psyence Biomed Initiates Phase IIb Psilocybin Trial for Adjustment Disorder in Palliative Care

  • Psyence Biomed has initiated its Phase IIb clinical trial in Australia, evaluating nature-derived psilocybin for adjustment disorder in palliative care patients.
  • The trial is a randomized, double-blind, placebo-controlled study assessing two doses of psilocybin (10mg, 25mg) against a low-dose comparator (1mg) with psychotherapy.
  • Patient screening will commence imminently, with the first subject expected to be randomized into the study in October, and topline data anticipated in the back half of next year.
  • The study is supported by partnerships with Fluence and iNGENü CRO, marking a significant step in advancing psychedelic-based therapeutics for mental health disorders.

VCU Health Trials Novel eShunt for Normal Pressure Hydrocephalus

  • VCU Health is participating in a clinical trial evaluating the CereVasc® eShunt® Implant for treating normal pressure hydrocephalus (NPH).
  • The eShunt offers a less invasive alternative to traditional VP shunts, using a small leg incision for placement within blood vessels.
  • Early results from the pilot study show promise, with patients like Bill Hobgood experiencing significant symptom relief and quicker recovery.
  • VCU Health's long-standing NPH clinic and contributions to diagnostic guidelines position it as a key site for this innovative trial.

Radiation Therapy Alone Shows Promise in Low-Risk Nasopharyngeal Carcinoma

  • A Chinese phase III trial reveals that radiation therapy alone is non-inferior to chemoradiation for low-risk nasopharyngeal carcinoma, offering similar survival rates.
  • The study, involving 341 patients, demonstrated comparable 5-year overall survival and failure-free survival between radiation alone and chemoradiation.
  • Patients receiving radiation alone experienced significantly fewer grade 3 or 4 adverse events and reported better quality-of-life scores during treatment.
  • The findings suggest radiation alone could be an effective and safer treatment option for low-risk nasopharyngeal carcinoma, reducing toxic side effects.

Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era

NCT02633202Unknown StatusPhase 3
Sun Yat-sen University
Posted 11/1/2015

AstraZeneca's Datopotamab TL01 Shows Promise in Lung Cancer, Phase III Trial Anticipated

  • AstraZeneca's datopotamab TL01 study showed positive biomarker data in second-line lung cancer, particularly in non-squamous patients, potentially explaining efficacy imbalances.
  • Bank of America Securities maintained a Buy rating on AstraZeneca's stock, citing the biomarker data and upcoming AVANZAR phase III trial as significant catalysts.
  • The AVANZAR phase III trial, expected in the second half of 2025, targets first-line non-small cell lung cancer (NSCLC) and has potential for substantial market impact.
  • Final overall survival data from the TL01 study is imminent and is expected to influence regulatory discussions and the FDA approval decision.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.